Gregory Perry
Non-Executive Director
bioinformatics and system biology
Merus
Netherlands
Biography
Gregory Perry has been a member of our board since May 2016. Mr. Perry has been the chief financial and administrative officer of Novelion Therapeutics, a biopharmaceutical company, since July 2015. Prior to joining Novelion Therapeutics, Mr. Perry served as chief financial and business officer of Eleven Biotherapeutics, Inc., a biopharmaceutical company, from December 2013 to July 2015, as interim chief financial officer of InVivo Therapeutics Holding Corp., a biotechnology company, from September 2013 to December 2013, and as chief financial officer of ImmunoGen, Inc., a biopharmaceutical company, from January 2009 to September 2013. Mr. Perry currently serves as a director of a private biopharmaceutical company and previously served as a director of Ocata Therapeutics, Inc. from December 2011 to February 2016, when it was acquired by Astellas Pharma Inc. Mr. Perry holds a B.A. in economics and political science from Amherst College.
Research Interest
Next Generation Sequencing & Applications
